Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs

Total Page:16

File Type:pdf, Size:1020Kb

Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs LABORATORY SCIENCES Inhibition of Histamine-Induced Human Conjunctival Epithelial Cell Responses by Ocular Allergy Drugs John M. Yanni, PhD; Lori K. Weimer, BA; Najam A. Sharif, PhD; Shou X. Xu, MS; Daniel A. Gamache, PhD; Joan M. Spellman, MS Objective: To evaluate the effects of topical ocular drugs secretion (50% inhibitory concentration, 1.7-5.5 nmol/L) with histamine H1-antagonist activity on histamine- than predicted from binding data, while antazoline and stimulated phosphatidylinositol turnover and interleu- pheniramine were far less potent (20- to 140-fold) in func- kin (IL) 6 and IL-8 secretion from human conjunctival tional assays. Levocabastine (dissociation constant, 52.6 epithelial cells. nmol/L) exhibited greater functional activity (50% in- hibitory concentration, 8-25 nmol/L) than either antazo- Methods: Primary human conjunctival epithelial cell cul- line or pheniramine. tures were stimulated with histamine in the presence or ab- sence of test drugs. Phosphatidylinositol turnover was quan- Conclusions: Histamine-stimulated phosphatidylino- tified by ion exchange chromatography and cytokine con- sitol turnover and cytokine secretion by human conjunc- tentofsupernatantsbyenzyme-linkedimmunosorbentassay. tival epithelial cells are attenuated by compounds with H1-antagonist activity. However, antihistaminic po- Results: Antazoline hydrochloride, emedastine difuma- tency alone does not predict anti-inflammatory poten- rate, levocabastine hydrochloride, olopatadine hydro- tial. Olopatadine, emedastine, and levocabastine were no- chloride, and pheniramine maleate attenuated histamine- tably more potent than pheniramine and antazoline. stimulated phosphatidylinositol turnover and IL-6 and IL-8 secretion. Emedastine was the most potent in li- Clinical Relevance: Selected topical ocular drugs with gand binding, phosphatidylinositol turnover, and IL-6 se- antihistaminic activity may offer therapeutic advan- cretion, with dissociation constant and 50% inhibitory tages to patients with allergic conjunctivitis by inhibit- concentrations of 1-3 nmol/L. Olopatadine, antazoline, ing proinflammatory cytokine secretion from human con- and pheniramine exhibited similar H1-binding affinities junctival epithelial cells. (32-39 nmol/L). However, olopatadine was approxi- mately 10-fold more potent as an inhibitor of cytokine Arch Ophthalmol. 1999;117:643-647 UMAN CONJUNCTIVAL epi- enhanced by exposure to 1-µmol/L hista- thelial cells (HCEs) se- mine.2 In addition, histamine caused a crete cytokines after dose-dependent stimulation of IL-6, IL-8, stimulation by various and GM-CSF release by normal and trans- cell-activating agents. formed human bronchial epithelial cells 1 Gamache et al showed that primary cul- that appeared to occur via histamine H1- H 3 tures of HCEs secrete tumor necrosis fac- receptor activation. The proinflamma- tor a, interleukin (IL) 6, IL-8, and granu- tory properties of these cytokines are well locyte-macrophage colony-stimulating documented. Elevated IL-6 levels have factor (GM-CSF) after IL-1a, phorbol my- been reported to be associated with a va- ristate acetate, and calcium ionophore riety of inflammatory conditions, includ- A23187 treatment. The authors suggested ing asthma, psoriasis, uveitis, and aller- that this capability of the conjunctival epi- gic rhinitis.4-7 Intravitreal injection of IL-6 thelium indicates a possible effector func- has been shown to produce uveitis in rats tion for the tissue in allergic conjunctivi- and rabbits.8 Interleukin 8 is a potent mem- tis. Other investigators have reported that ber of the C-X-C family of chemokines. It histamine, a major mediator of allergic dis- promotes integrin expression, neutro- eases, induces the production of cyto- phil degranulation, and chemotaxis of ba- 9-13 From Ophthalmic Products kines by airway epithelium. For in- sophils and eosinophils. Research, Alcon Laboratories stance, GM-CSF release from human The presence of these polymorpho- Inc, Fort Worth, Tex. tracheal epithelial cells was significantly nuclear leukocytes (primarily eosino- ARCH OPHTHALMOL / VOL 117, MAY 1999 643 ©1999 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 MATERIALS AND METHODS performed as previously described21 with minor modifica- tions. The HCEs were incubated with tritiated ([3H]) myoinositol (0.037 MBq/0.5 mL; 55.5-62.9 3 1010 Bq/ CELL CULTURES mmol; Amersham Life Science, Inc, Arlington Heights, Ill) in Dulbecco modified Eagle medium (GIBCO, Gaithers- Methods detailing the preparation of primary epithelial cell burg, Md) for 24 hours in 5% carbon dioxide at 37°C to cultures and cytokine release studies with the use of these cells label the cell membrane lipids. Cells were then exposed to have been described.1 Briefly, cultures of HCEs were initiated histamine (10 nmol/L to 1 mmol/L) for 60 minutes at 23°C. from donor tissues obtained by various eye banks within 8 To determine the potencies of the antagonists, the drugs hours post mortem. The tissues were enzymatically digested were added to the cells 20 minutes before the addition of overnight. Epithelial cells were gently scraped from the tis- histamine (100 µmol/L). The assay was terminated by the sue surface, dissociated into a single cell suspension, and cul- addition of ice-cold 0.1-mol/L formic acid. With ion ex- tured in Clonetics keratinocyte growth medium (Biowhittaker change columns containing 1 mL of AG1-X8 resin in for- Corp, Walkersville, Md). Cells were used only through pas- mate form, free [3H]myoinositol was removed from the cell sage 6. Cultures were maintained in a preconfluent state to lysates with deionized water; the water-soluble [3H]inosi- prevent differentiation. Cells were identified as epithelial by tol phosphates were then eluted with 1.2-mol/L ammo- positive keratin staining, as described previously.1 nium formate. The [3H]inositol phosphates were quanti- fied by liquid scintillation spectrometry. CYTOKINE ASSAYS DATA ANALYSIS Several compounds with histamine H1-antagonist activity were evaluated for their ability to inhibit secretion of cy- The antagonist potency (IC50) was defined as the concen- tokines (IL-6 and IL-8) from cultured HCEs in response tration of the drug required to produce 50% inhibition of to histamine stimulation. Cells were plated at 2 3 104 cells the agonist-stimulated functional response. Data derived per well and cultured overnight in 5% carbon dioxide at from the cytokine assays were calculated as mean and SEM 37°C. The following day, keratinocyte growth medium con- values that represent the variability among identically treated taining test compound was added directly to wells and the culture wells. The dose-dependent effect of pharmacologi- cells were incubated for 30 minutes before 24-hour stimu- cal agents and IC50s were determined by linear regression. lation with histamine (30 µmol/L). Three culture wells were Data obtained in the PI turnover assays were analyzed by used for each treatment group. At harvest, cell monolay- means of a nonlinear, iterative curve fitting program as pre- ers were examined microscopically to confirm viability and viously described.18,20 Data are expressed as mean ± SEM supernatants were collected, centrifuged at 200g, and stored from 3 to 5 independent experiments. at −20°C. Samples were analyzed for IL-6 and IL-8 by en- zyme-linked immunosorbent assay (R&D Systems, Min- TEST COMPOUNDS neapolis, Minn) as directed by the manufacturer. The sen- sitivities of each enzyme-linked immunosorbent assay are Compounds were obtained as follows: antazoline hydro- 0.7 pg/mL for IL-6 and 3.0 pg/mL for IL-8. chloride and pheniramine maleate (Sigma-Aldrich Corp, St Louis, Mo); emedastine difumarate (Kanebo Ltd, Osaka, HISTAMINE-INDUCED Japan); olopatadine hydrochloride (Kyowa Hakko Kogyo PHOSPHATIDYLINOSITOL TURNOVER Co Ltd, Tokyo, Japan); and levocabastine hydrochloride (Livostin; Ciba Vision Ophthalmics, Atlanta, Ga). Hista- The determination of phosphatidylinositol (PI) turnover mine dihydrochloride was obtained from Research Bio- induced by stimulation of phospholipase C in HCEs was chemicals International, Natick, Mass. phils) contributes to the pathogenesis of the late-phase HCEs. These receptors were coupled to inositol phos- allergic response. Degranulation of the eosinophilic leu- phate generation, which mobilized intracellular cal- kocytes leads to the release of major basic protein, eo- cium. Calcium mobilization peaked within 10 seconds sinophil peroxidase, eosinophil cationic protein, and eo- and was sustained for 20 minutes after stimulation with sinophil-derived neurotoxin.14 Reports have demonstrated histamine. Pharmacological studies indicated that his- that the eosinophil-derived proinflammatory mediator, tamine H1-receptor antagonists potently antagonized these major basic protein, has the ability to activate neutro- effects. Recently, Weimer et al19 demonstrated that phils as well as stimulating additional histamine re- histamine stimulation of HCEs induced the secretion of lease, further amplifying the allergic response.15 IL-6, IL-8, and GM-CSF in a concentration- and time- Elevated levels of histamine in tears of patients with dependent manner. They also presented evidence that the allergic ocular diseases have been reported. Tears col- potent H1-antagonist emedastine inhibited cytokine se- lected after ocular antigen challenge contained signifi- cretion at concentrations consistent with its published 20 cantly more histamine than tears collected after
Recommended publications
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • HMSA Drug Formulary
    March 23, 2004 MEMORANDUM TO: Participating Pharmacies FROM: John T. Berthiaume, M.D. Medical Director, Pharmacy Management SUBJECT: Updated HMSA Drug Formulary Enclosed is the comprehensive updated formulary, effective April 1. This copy incorporates the changes listed in the Formulary Update sent to you in February. Please replace the current formulary sections in your pharmacy handbook with the enclosed version. If you have any questions, please call an HMSA Provider Teleservice Representative at 948- 6330 on Oahu or 1 (800) 790-4672 from the Neighbor Islands. PM04-010 HMSA DRUG FORMULARY 4/1/04 - Page 1 Code THERAPEUTIC CATEGORY LISTING 1 I. Anti-infectives A. Antibiotics 1. Penicillins - non-penicillinase resistant 2 I. Anti-infectives A. Antibiotics 2. Penicillins - penicillinase resistant 3 I. Anti-infectives A. Antibiotics 3. Cephalosporins 4 I. Anti-infectives A. Antibiotics 4. Fluoroquinolones 5 I. Anti-infectives A. Antibiotics 5. Tetracyclines 6 I. Anti-infectives A. Antibiotics 6. Macrolides 7 I. Anti-infectives A. Antibiotics 7. Vancomycin 8 I. Anti-infectives A. Antibiotics 8. Lincosamides 9 I. Anti-infectives A. Antibiotics 9. Aminoglycoside 10 I. Anti-infectives A. Antibiotics 10. Sulfonamides 11 I. Anti-Infectives A. Antibiotics 11. Vaginal preparations 12 I. Anti-infectives B. Antifungal agents 1. Oral 13 I. Anti-Infectives B. Antifungal agents 2. Vaginal preparations OTC considerations: clotrimazole (Gyne-Lotrimin 3, Mycelex-7), miconazole (Monistat 7), tioconazole (Vagistat-1), butoconazole (Femstat 3) 14 I. Anti-infectives C. Antimalarial 15 I. Anti-infectives D. Antituberculous 16 I. Anti-infectives E. Amebicides 17 I. Anti-infectives F. Antiviral agents 1. Nucleoside Reverse-transcriptase Inhibitors (NRTI) 18 I.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Emadine, INN-Emedastine
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT EMADINE 0.5 mg/ml, eye drops, solution 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml of solution contains emedastine 0.5 mg (as difumarate) Excipient with known effect Benzalkonium chloride 0.1 mg/ml For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Eye drops, solution. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Symptomatic treatment of seasonal allergic conjunctivitis. 4.2 Posology and method of administration EMADINE has not been studied in clinical trials beyond six weeks. Posology The dose is one drop of EMADINE to be applied to the affected eye(s) twice daily. When used with other ophthalmic medicines, an interval of ten minutes should be allowed between applications of each medicinal product. Eye ointments should be administered last. Elderly population EMADINE has not been studied in elderly patients older than 65 years, and therefore its use is not recommended in this population. Paediatric population EMADINE may be used in paediatric patients (3 years of age and older) at the same posology as in adults. Hepatic and Renal impairment Use EMADINE has not been studied in these patients and therefore, its use is not recommended in this population. Method of administration For ocular use. 2 To prevent contamination of the dropper tip and solution, care should be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. After cap is removed, if tamper evident snap collar is loose, remove before using product.
    [Show full text]
  • Determination of Antidepressants in Human Plasma by Modified Cloud
    pharmaceuticals Article Determination of Antidepressants in Human Plasma by Modified Cloud-Point Extraction Coupled with Mass Spectrometry El˙zbietaGniazdowska 1,2 , Natalia Korytowska 3 , Grzegorz Kłudka 3 and Joanna Giebułtowicz 3,* 1 Łukasiewicz Research Network, Industrial Chemistry Institute, 8 Rydygiera, 01-793 Warsaw, Poland; [email protected] 2 Department of Bioanalysis and Drugs Analysis, Doctoral School, Medical University of Warsaw, 61 Zwirki˙ i Wigury, 02-091 Warsaw, Poland 3 Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha, 02-097 Warsaw, Poland; [email protected] (N.K.); [email protected] (G.K.) * Correspondence: [email protected] Received: 5 October 2020; Accepted: 7 December 2020; Published: 12 December 2020 Abstract: Cloud-point extraction (CPE) is rarely combined with liquid chromatography coupled to mass spectrometry (LC–MS) in drug determination due to the matrix effect (ME). However, we have recently shown that ME is not a limiting factor in CPE. Low extraction efficiency may be improved by salt addition, but none of the salts used in CPE are suitable for LC–MS. It is the first time that the influences of a volatile salt—ammonium acetate (AA)—on the CPE extraction efficiency and ME have been studied. Our modification of CPE included also the use of ethanol instead of acetonitrile to reduce the sample viscosity and make the method more environmentally friendly. We developed and validated CPE–LC–MS for the simultaneous determination of 21 antidepressants in plasma that can be useful for clinical and forensic toxicology. The selected parameters included Triton X-114 concentration (1.5 and 6%, w/v), concentration of AA (0, 10, 20 and 30%, w/v), and pH (3.5, 6.8 and 10.2).
    [Show full text]
  • Otrivine-Antistin-Uk-Spc-09Jan19.Pdf
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Otrivine Antistin Eye Drops Xylometazoline 0.05% w/v Antazoline 0.5% w/v 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Xylometazoline hydrochloride 0.05% Antazoline sulphate 0.5% For excipients see Section 6.1. 3. PHARMACEUTICAL FORM Eye drops solution A clear colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications For the temporary relief of redness and itching of the eye due to seasonal and perennial allergies such as hay fever or house dust allergy. 4.2 Posology and method of administration For local administration to the eye. Adults: 1 or 2 drops instilled 2 - 3 times a day. Children: No specific studies are available in this patient group. Due to possible systemic effects, Otrivine-Antistin is not recommended for use in children younger than 12 years of age. Elderly: One drop instilled 2 to 3 times a day. Otrivine Antistin Eye Drops should not be used for more than seven consecutive days. The dispenser remains sterile until the original closure is broken. Patients must be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures as this may contaminate the solution. If more than one medication needs to be instilled in the eye, an interval of at least 5 minutes between application of the different medicinal products must be allowed. 4.3 Contraindications Hypersensitivity to any of the ingredients of the formulation Presence of narrow angle glaucoma Use with contact lenses Use in patients receiving monoamine oxidase inhibitors or within 14 days of stopping such treatment (See section 4.5) 4.4 Special warnings and precautions for use Like other topically applied ophthalmic drugs, Otrivine-Antistin may be absorbed systemically and occasionally cause systemic sympathomimetic effects such as hypertension, nervousness, nausea, dizziness, headache, insomnia, palpitation, tachycardia, and arrhythmia.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Comparative Study of 0.1% Olopatadine Hydrochloride and 0.5% Ketorolac Tromethamine in the Treatment of Seasonal Allergic Conjunctivitis
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE ACTA OPHTHALMOLOGICA SCANDINAVICA 2003 Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis Volkan Yaylali, Ibrahim Demirlenk, Sinan Tatlipinar, Davut O¨zbay, Arif Esme, Cem Yildirim and Serap O¨zden Pamukkale University School of Medicine, Department of Ophthalmology, Denizli, Turkey ABSTRACT. Purpose: To compare the therapeutic effects of two ophthalmic solutions (0.1% Introduction olopatadine hydrochloride and 0.5% ketorolac tromethamine) with different Seasonal allergic conjunctivitis (SAC) pharmacological mechanisms on the clinical signs and Symptoms of seasonal or hay fever is a common allergic dis- allergic conjunctivitis (SAC). ease typically elicited by airborne aller- Methods: Forty patients with the signs and symptoms of SAC (i.e. hyperaemia, gens such as pollen, grass, weeds and itching, mucus discharge, tearing) were included in this placebo-controlled, ran- animal dander (Abelson & Schaefer domized, parallel group, single centre study. In group 1 (20 patients) one eye of 1993). It is a type 1 hypersensitivity each patient was treated with olopatadine and the other with placebo. In group 2 reaction mediated by IgE in response (20 patients) one eye of each patient was treated with ketorolac solution and the to these environmental antigens. The other with placebo. The principal signs and symptoms of SAC (hyperaemia and principal symptom of SAC is ocular itching) were evaluated at 30 mins and at 2, 7 and 15 days. itching (Abelson & Schaefer 1993). Results: In group 1, both parameters improved significantly in eyes treated with Other signs and symptoms include con- olopatadine compared with those receiving placebo at all control examinations junctival hyperaemia, tearing, mucus (all p < 0.05).
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • With [3H]Mepyramine (Trieyclic Antidepressants/Antihistamine/Neurotransmitter/Amitriptyline) VINH TAN TRAN, RAYMOND S
    Proc. Nati. Acad. Sci. USA Vol. 75, No. 12, pp. 6290-6294,, December 1978 Neurobiology Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine (trieyclic antidepressants/antihistamine/neurotransmitter/amitriptyline) VINH TAN TRAN, RAYMOND S. L. CHANG, AND SOLOMON H. SNYDER* Departments of Pharmacology and Experimental Therapeutics, and Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 Communicated by Julius Axelrod, August 30,1978 ABSTRACT The antihistamine [3H mepyramine binds to Male Sprague-Dawley rats (150-200 g) were killed by cer- HI histamine receptors in mammalian brain membranes. vical dislocation, their brains were rapidly removed and ho- Potencies of H1 antihistamines at the binding sites correlate mogenized with a Polytron for 30 min (setting 5) in 30 vol of with their pharmacological antihistamine effects in the guinea pig ileum. Specific [3Himepyramine binding is saturable with ice-cold Na/K phosphate buffer (50 mM, pH 7.5), and the a dissociation constant of about 4 nM in both equilibrium and suspension was centrifuged (50,000 X g for 10 min). The pellet kinetic experiments and a density of 10pmolper gram ofwhole was resuspended in the same volume of fresh buffer and cen- brain. Some tricyclic antidepressants are potent inhibitors of trifuged, and the final pellet was resuspended in the original secific [3Hmepamine binding. Regional variations of volume of ice-cold buffer by Polytron homogenization. Calf [3Hjmepyramine ing do not correlate with variations in brains were obtained from a local abattoir within 2 hr after the endogeneous histamine and histidine decarboxylase activity. death of the animals and transferred to the laboratory in ice- Histamine is a neurotransmitter candidate in mammalian brain cold saline.
    [Show full text]
  • A Practical Approach to Management of Allergic Eye Conditions in Children
    Volume 6 No. 3, September 2010 Review Article A Practical Approach to Management of Allergic Eye Conditions in Children Dexter Yu-Lung LEUNG Hong Kong Eye Hospital; Department of Ophthalmology & Visual Sciences, The Chinese University of Hong Kong; and Hong Kong Ophthalmological Society, Hong Kong Introduction In USA, expenditure related to ocular prescription medication rose from US$6 million in early 1990s to While nasal allergy all along has been important in >US$200 million in the new millennium, projecting an allergy research, ocular allergy is now increasingly annual growth of 25% per year in USA.7 recognized as a distinct symptoms-and-signs complex that imposes significant disease burden with reduction of quality of life of patients. Allergic conjunctivitis is Classification highly prevalent in Hong Kong and has a close epidemiologic relationship with allergic rhinitis. The emphasis of this article will also be on what a paediatrician can do prior to the point of referral: recognition of the ocular symptoms, recognition of potential sight-threatening situations, and effective initial treatment. Disease burden While we are still awaiting published evidence for official incidence of ocular allergy in Hong Kong, a recent survey from the Eye Institute of the University of Hong Kong, conducted during May and June 2009 on 1,000 parents with children less than 12 years old in Hong Kong, has estimated that approximately 30% SAC and PAC are more common, and while they are of children suffered from eye allergy.1 symptomatic, they are less likely to result in long term ocular complications. VKC and AKC are rarer, more The incidence of ocular allergy varies in different chronic but are potentially associated with severe geographical regions and tends to be more common blinding ocular complications.
    [Show full text]